Cardiac muscle regeneration using mesenchymal stem cells
AssigneeOsiris Therapeutics, Inc.
InventorsMark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.
Claims20
A method for producing cardiomyocytes in the heart of an individual, comprising:
- administering directly to the heart of the individual a cardiomyocyte producing amount of allogeneic mesenchymal stem cells, wherein the mesenchymal stem cells differentiate into cardiomyocytes in the heart of the individual.
A method for producing cardiomyocytes in the heart of an individual, comprising:
- administering directly to the heart of the individual a cardiomyocyte producing amount of autologous mesenchymal stem cells, wherein the mesenchymal stem cells differentiate into cardiomyocytes in the heart of the individual.
Dependencies are inferred from the claim text.